Alpha 2.0
Login Register
» Articles » PMID: 23648912

An Opportunistic Infection Associated with Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2013 May 8
PMID 23648912
Citations 61
Authors
Nicholas G Wysham
Donald R Sullivan
Gopal Allada
Affiliations
Soon will be listed here.
Abstract

We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class.

Citing Articles

Cryptococcosis Associated With Biologic Therapy: A Narrative Review.

Li X, Paccoud O, Chan K, Yuen K, Manchon R, Lanternier F Open Forum Infect Dis. 2024; 11(7):ofae316.

PMID: 38947739 PMC: 11212009. DOI: 10.1093/ofid/ofae316.

Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal Infections.

Chiu C, John T, Matsuo T, Wurster S, Hicklen R, Khattak R J Fungi (Basel). 2024; 10(4).

PMID: 38667935 PMC: 11051496. DOI: 10.3390/jof10040264.

Integrated Stress Response (ISR) Pathway: Unraveling Its Role in Cellular Senescence.

Kalinin A, Zubkova E, Menshikov M Int J Mol Sci. 2023; 24(24).

PMID: 38139251 PMC: 10743681. DOI: 10.3390/ijms242417423.

Ruxolitinib inhibits cytokine production by human lung macrophages without impairing phagocytic ability.

Mantov N, Zrounba M, Brollo M, Grassin-Delyle S, Glorion M, David M Front Pharmacol. 2022; 13:896167.

PMID: 36059986 PMC: 9437255. DOI: 10.3389/fphar.2022.896167.

Cryptococcal infection with ruxolitinib in primary myelofibrosis: A case report and literature review.

Ciochetto Z, Wainaina N, Graham M, Corey A, Abid M Clin Case Rep. 2022; 10(2):e05461.

PMID: 35369391 PMC: 8858788. DOI: 10.1002/ccr3.5461.

References
1.
Voelz K, May R . Cryptococcal interactions with the host immune system. Eukaryot Cell. 2010; 9(6):835-46. PMC: 2901644. DOI: 10.1128/EC.00039-10. View
2.
Tefferi A . Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms. N Engl J Med. 2012; 366(9):844-6. DOI: 10.1056/NEJMe1115119. View
3.
Garber K . Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nat Biotechnol. 2011; 29(6):467-8. DOI: 10.1038/nbt0611-467. View
4.
Verstovsek S, Mesa R, Gotlib J, Levy R, Gupta V, Dipersio J . A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366(9):799-807. PMC: 4822164. DOI: 10.1056/NEJMoa1110557. View
5.
Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N . Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2010; 70(4):616-23. DOI: 10.1136/ard.2010.137422. View